Stock Taper
| DATE | TYPE | RATIO |
|---|---|---|
| 2023-10-11 | Reverse | 1:7 |
| 2019-06-10 | Reverse | 1:6 |
| 2018-05-07 | Reverse | 1:7 |
| 2015-09-02 | Reverse | 1:10 |
Edesa Biotech, Inc. is a Canadian biopharmaceutical company developing clinical-stage drugs for inflammatory and immune diseases, with lead candidates EB05 for COVID-19-related ARDS and EB01 for allergic contact dermatitis.

EB06 is a clinical-stage anti-CXCL10 monoclonal antibody by Edesa Biotech, developed as a potential vitiligo therapy, with ongoing manufacturing and plans for FDA regulatory submissions.
| Icon | PRODUCT | Q3-2018 | Q4-2018 | Q1-2019 | Q2-2019 |
|---|---|---|---|---|---|
![]() | Product | $73.05K | $54.26K ▼ | $53.03K ▼ | $117.75K ▲ |
Overall rating: C-
| PEER | PRICE | |
|---|---|---|
DWTX | $2.65 | COMPARE |
COCP | $1.10 | COMPARE |
TRAW | $0.59 | COMPARE |
IMRN | $1.15 | COMPARE |
IMNN | $1.60 | COMPARE |
BRTX | $0.20 | COMPARE |
EVGN | $0.55 | COMPARE |
OSRH | $0.12 | COMPARE |